Prostate Biopsy Standards
Rising Infection Rates
“From 1996 to 2005 the rate of readmission for sepsis post-transrectal biopsy in Canadian men rose from 0.6% to 3.6%.”4
Fluoroquinolone resistant bacteria, which is responsible for most cases of sepsis, is often greater in patients post-transrectal prophylactics than prior.3 In 2016, the FDA announced that fluoroquinolones should only be used as a last resort due to the risk of “disabling and potentially permanent side effects of the tendons, muscles, joints, nerves, and central nervous system that can occur together in the same patient”.1 As a result, transrectal biopsy prophylactics now encompass other broad spectrum antibiotics such as multi-drug prophylactics or culture-specific prophylactics. These methods may be successful, resulting in a less than 1% sepsis rate, but they directly contradict the warnings from the CDC and WHO by using more or more powerful antibiotics.1
The Transperineal Approach- Why The Uptake Is Slow
“The rate of sepsis post-transperineal biopsy is nearly 0%, which is 40 to 70 times less than that of transrectal.”4
To tackle the rising sepsis rate, transperineal biopsies offer a clean solution by passing the needle through the perineum, rather than the rectum, thereby eliminating the need for fluoroquinolone prophylactics.1 The rate of sepsis post-transperineal biopsy is nearly 0%, which is 40 to 70 times less than that of transrectal, yet there is no significant difference in detection rates.4 Despite this major advantage, the transition to transperineal has been slow due to the perceived need for general anesthesia, specialized equipment and higher associated costs.5
Addressing Perceived Issues: Learning Curve, Procedure Time and Detection Rates
“It (transperineal biopsy) is becoming widely accepted as the superior method for targeting the anterior and apical regions, even in an MRI-targeted context.”1
Modern research proves MRI-targeted transperineal biopsies can be easier to learn, more effective and less costly than previously expected. Within 30-50 procedures, trainee urologists, with less than 1 year of experience, achieved similar times (13 min and 9 min) and detection rates (73% and 68%) to senior urologists, while performing systematic transperineal biopsies with MRI-targeted biopsies.7
In contrast to most MRI-US fusion systems, the Fusion Bx has no learning curve between the transrectal and transperineal approaches because the equipment and software interface are the same in both cases.8
The MRI-US fusion transperineal biopsy has the potential to become the new “gold standard” as it addresses both major concerns of accuracy and infection.2 It is becoming widely accepted as the superior method for targeting the anterior and apical regions, even in an MRI-targeted context.1,5,9 Sampling through the perineum also results in longer core lengths, which provides more prognostic information from the biopsy. Some studies have even shown MRI-US fusion transperineal biopsies to outperform the transrectal approach, by as much as 10%.9 Compared to transrectal biopsies, where the probe may be moved in the pitch, yaw and rotational directions, transperineal ultrasound probes are limited to rotation, which may reduce patient discomfort and overall movement.8
General vs. Local Anesthesia
“20% of patients refused to undergo biopsy without anesthesia, thus making effective anesthesia an important factor for successful biopsies.”11
Transperineal biopsies performed under local anesthesia may be becoming more prevalent as a cost friendly option for providers, but how do the patients feel? In short, not too bad. In 2017, a study tested the tolerability of patients when administered local anesthesia and a periprostatic nerve block (PNB) prior to an MRI-targeted transperineal biopsy. Using a brachytherapy stepper and grid, a minimum of 4 cores were taken via cognitive fusion. The procedure was performed by one doctor with two assistants in an average of 27 minutes. The median visual analog scale (VAS) pain score during the biopsy was rated 1/10. 89% of patients were not dissatisfied and would recommend the procedure to others.10
To Sum It All Up
The Fusion Bx: A Simple All-in-One Prostate Biopsy Solution
Whether taking the transrectal or transperineal approach, Focal Healthcare’s Fusion Bx is the simple MRI-targeted fusion prostate biopsy solution. The unique semi-robotic arm allows freehand-like access to the entire gland, while maintaining consistent probe pressure on the prostate to minimize prostate deformation. The hands-free counterbalance keeps the probe steady in any position, which reduces the need for additional assistance. Using buttons on the stepper, physicians can advance through the simplified 4-step guided workflow without having to take their hands off the probe. Patient movement is typically more prevalent in biopsies, whether transrectal or transperineal, when performed under local anesthesia. Using our motion compensation feature, any movement is automatically adjusted for by maintaining MRI-US coupling, so procedures may continue uninterrupted.
As the likelihood for needle deflection increases with the distance and mass the needle must pass through, the ability to account for deviation is even more important with transperineal biopsies. Compared to other systems, the Fusion Bx software displays the live ultrasound view, in addition to the 3D model, which shows the projected needle path and core locations. By visualizing the difference between the projected and actual needle path, physicians can more accurately account for any needle deflection (Fig.4- 5).
In combination with the arm, stepper and software, physicians can seamlessly transition between either approach because the setup and workflow are the same in both cases. Using a system like the Fusion Bx not only eliminates the cost of specialized hardware and software, but also the time spent setting up or taking down the equipment for transperineal biopsies. For hospitals and clinics that reserve transperineal biopsies for a minority of cases, or are in the process of making the switch, the Fusion Bx offers the flexibility to support all of your biopsy needs. For more information download our brochure or contact us at email@example.com.
1 Grummet, J., Pepdjonovic, L., Huang, S., Anderson, E., & Hadaschik, B. (2017). Transperineal vs. transrectal biopsy in MRI targeting. Translational Andrology and Urology, 6(3), 368–375. doi: 10.21037/tau.2017.03.58
2 Xiang, J., Yan, H., Li, J., Wang, X., Chen, H., & Zheng, X. (2019). Transperineal versus transrectal prostate biopsy in the diagnosis of prostate cancer: a systematic review and meta-analysis. World Journal of Surgical Oncology, 17(1). doi: 10.1186/s12957-019-1573-0
3 Zowawi, H. M., Harris, P. N. A., Roberts, M. J., Tambyah, P. A., Schembri, M. A., Pezzani, M. D., … Paterson, D. L. (2015). The emerging threat of multidrug-resistant Gram-negative bacteria in urology. Nature Reviews Urology, 12(10), 570–584. doi: 10.1038/nrurol.2015.199
4 Grummet, J. P., Weerakoon, M., Huang, S., Lawrentschuk, N., Frydenberg, M., Moon, D. A., … Murphy, D. (2014). Sepsis and ‘superbugs’: should we favour the transperineal over the transrectal approach for prostate biopsy?. BJU International, 114(3). doi: 10.1111/bju.12536
5 Patel, P. (2020, February). The case for transperineal prostate biopsy vs. the transrectal approach. Urology Times, 48(2), 16–17.
6 Gross, M. D., Alshak, M. N., Shoag, J. E., Laviana, A. A., Gorin, M. A., Sedrakyan, A., & Hu, J. C. (2019). Healthcare Costs of Post-Prostate Biopsy Sepsis. Urology, 133, 11–15. doi: 10.1016/j.urology.2019.06.011
7 Ito*, M., Kataoka, M., Takemura, K., Suzuki, H., Sakamoto, K., Nakanishi, Y., … Koga, F. (2019). Mp13-11 Learning Curves, Cancer Detection Rates, And Complications Of Transperineal Prostate Biopsy Under Local Anesthesia By Trainee Urologists. Journal of Urology, 201(Supplement 4). doi: 10.1097/01.ju.0000555224.35839.bf
8 Tzeng, M., Cricco-Lizza, E., Awamlh, B. A. H. A., Pantuck, M., Margolis, D. J., Yu, M., & Hu, J. (2019). IDEAL Stage 2a experience with in-office, transperineal MRI/ultrasound software fusion targeted prostate biopsy. BMJ Surgery, Interventions, & Health Technologies, 1(1). doi: 10.1136/bmjsit-2019-000025
9 Wallis, C. (2019, May). AUA 2019: Transperineal vs. Transrectal MRI/US Fusion for Prostate Cancer Detection.
10 Bass, E. J., Donaldson, I. A., Freeman, A., Jameson, C., Punwani, S., Moore, C., … Ahmed, H. U. (2017).Magnetic resonance imaging targeted transperineal prostate biopsy: a local anaesthetic approach. Prostate Cancer and Prostatic Diseases, 20(3), 311–317. doi: 10.1038/pcan.2017.13
11 Ding, X.-F., Huang, T.-B., Lu, S.-M., Tao, H.-Z., Ye, X.-F., Wang, F., … Luan, Y. (2019). Pelvic plexus block to provide better anesthesia in transperineal template-guided prostate biopsy: a randomised controlled trial. BMC Urology, 19(1), 63. doi: 10.1186/s12894-019-0496-y
12 Kasivisvanathan, V., Rannikko, A. S., Borghi, M., Panebianco, V., Mynderse, L. A., Vaarala, M. H., . . . Moore, C. M. (2018). MRI-Targeted or Standard Biopsy for Prostate-Cancer Diagnosis. New England Journal of Medicine, 378(19), 1767–1777. doi:10.1056/nejmoa1801993
13 Tu, X., Liu, Z., Chang, T., Qiu, S., Xu, H., Bao, Y., … Wei, Q. (2019). Transperineal Magnetic Resonance Imaging–Targeted Biopsy May Perform Better Than Transrectal Route in the Detection of Clinically Significant Prostate Cancer: Systematic Review and Meta-analysis. Clinical Genitourinary Cancer, 17(5). doi: 10.1016/j.clgc.2019.05.006